血浆置换治疗ANCA相关血管炎严重肺泡出血的靶试验模拟
本研究采用靶试验模拟方法,基于全国多中心回顾性队列纳入184例ANCA相关血管炎合并严重弥漫性肺泡出血患者,比较血浆置换与未血浆置换的30天死亡率。结果显示两组30天生存率无显著差异(HR 1.23,95%CI 0.57-3.89),提示血浆置换未降低该人群30天死亡率。
要点
- 严重AAV相关DAH患者中,血浆置换组与未血浆置换组30天生存率无显著差异。
- 血浆置换组基线肾功能更差且环磷酰胺使用更频繁,但30天死亡率无显著获益。
- 该结果不支持对严重AAV相关DAH患者常规使用血浆置换以降低短期死亡率。
核心结论
- 在模拟的靶试验中,血浆置换未降低严重ANCA相关血管炎相关弥漫性肺泡出血患者的30天死亡率。
研究设计与样本
- 采用靶试验模拟方法,基于全国多中心回顾性队列数据,纳入184例严重AAV相关DAH患者。
- 主要终点为ICU入住后30天死亡率,采用Cox模型校正预设混杂因素。
主要发现
- 144例(78.3%)接受血浆置换,40例(21.7%)未接受。
- 30天总生存率为85%;血浆置换组30天生存率85%(95%CI 81-90),未血浆置换组88%(95%CI 77-96)。
- 血浆置换与未血浆置换组死亡率无显著差异(HR 1.23;95%CI 0.57-3.89)。
- 次要结局两组间亦相似。
临床怎么用
- 对于严重AAV相关DAH患者,血浆置换不应常规用于降低30天死亡率,需结合个体情况权衡。
局限性
- 本研究为回顾性数据模拟靶试验,可能存在未测量混杂。
- 血浆置换组基线肾功能更差且环磷酰胺使用更多,提示存在适应证偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Patients with severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-related diffuse alveolar hemorrhage (DAH) face high mortality. In the PEXIVAS trial, plasma exchange (PLEX) did not reduce death or end-stage kidney disease, but only 9% had severe DAH. OBJECTIVES: This study aimed to assess whether PLEX lowers mortality in patients with severe DAH. METHODS: We emulated a target trial using retrospective data from a national multicenter cohort of patients with severe AAV-related DAH. The primary endpoint was 30-day mortality after intensive care unit (ICU) admission, analyzed using a Cox model adjusted for prespecified confounders. MEASUREMENTS AND MAIN RESULTS: We included 184 patients (median age 66 [53-75] years; 51% female; 51% with granulomatosis with polyangiitis; 53% MPO (Myeloperoxydase)-ANCA positive). Of these, 144 (78.3%) received PLEX, and 40 (21.7%) did not. Baseline characteristics were similar, except for more severe renal impairment (creatinine 357 vs 171 µmol/L, P = .01) and more frequent cyclophosphamide use (77% vs 55%, P = .01) in the PLEX group. Severity at ICU admission (median Simplified Acute Physiology Score II score: 42) and mechanical ventilation needs (54%) were comparable between groups. At 30 days, overall survival was 85%. No significant difference in mortality was observed between the PLEX and no-PLEX groups: 30-day survival was 85% (95% CI, 81-90) with PLEX vs 88% (95% CI, 77-96) without (hazard ratio, 1.23; 95% CI, 0.57-3.89). Secondary outcomes were also similar. CONCLUSIONS: In this emulated target trial, PLEX did not reduce 30-day mortality in patients with severe AAV-related DAH.
引用
- Sanna AC, Gendreau S, Desnos C, et al. Plasma exchange for severe alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: emulation of a target trial. Am J Respir Crit Care Med. 2026. PMID: 41738152. doi:10.1093/ajrccm/aamaf122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。